A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

NCT06122649 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: apremilast
DRUG: Placebo

Sponsor

Amgen